How is the SAB Biotherapeutics Inc today?

The SAB Biotherapeutics Inc today is trading in the down by -7.07% at 1.71.

What is SAB Biotherapeutics Inc Annual Net Profit?

SAB Biotherapeutics Inc Annual Net Profit rose 19.17% in the last year to $34.11 M. Its sector's average net profit growth for the last fiscal year was -11.04%.

What is SAB Biotherapeutics Inc Price to Earning Ratio?

SAB Biotherapeutics Inc Price to Earning Ratio is -0.46, which is negative.

What is SAB Biotherapeutics Inc Stock Price?

SAB Biotherapeutics Inc Stock Price fell 50.43% and underperformed its sector by 61.76% in the past year.

What is SAB Biotherapeutics Inc Quarterly Net profit?

SAB Biotherapeutics Inc Quarterly Net profit fell 3.4% YoY to $5.2 M. Its sector's average net profit growth YoY for the quarter was -212.78%.

What is SAB Biotherapeutics Inc Debt to Equity Ratio?

SAB Biotherapeutics Inc Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is SAB Biotherapeutics Inc Return on Equity(ROE)?

SAB Biotherapeutics Inc Return on Equity(ROE) for the last financial year was -81.92%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is SAB Biotherapeutics Inc Mutual Fund Holding?

SAB Biotherapeutics Inc Mutual Fund Holding increased by 0.01% in the last quarter to 5.18.

What is SAB Biotherapeutics Inc Interest Coverage Ratio?

SAB Biotherapeutics Inc Interest Coverage Ratio is -106.11, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is SAB Biotherapeutics Inc Institutional Holding?

SAB Biotherapeutics Inc Institutional Holding increased by 0.64% in the last quarter to 30.24.

SAB Biotherapeutics Inc XNAS: SABS

SAB Biotherapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: SAB Biotherapeutics Inc: Is Infosys Ltd. worth buying?
Item: SAB Biotherapeutics Inc
Rating: 1.16091675
Author: Trendlyne DVM scores

about

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, witho...

1.71 -0.13 (-7.07%)

63.92% Fall from 52W High

27,966 XNAS Volume

XNAS 21 May, 2025 5:30 PM (EDT)

Not Eligible

-

Expensive Valuation

13.2 / 100

Technically Bearish

33.3 / 100

No estimates available

SAB Biotherapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

SAB Biotherapeutics Inc FAQ

How is SAB Biotherapeutics Inc today?

SAB Biotherapeutics Inc today is trading in the red, and is down by -7.07% at 1.71.

How has SAB Biotherapeutics Inc performed historically?

SAB Biotherapeutics Inc is currently trading down -7.07% on an intraday basis. In the past week the stock fell -9.04%. stock has been down -12.31% in the past quarter and fell -50.43% in the past year. You can view this in the overview section.